The study, which was conducted in normal adult volunteers, showed that LT-NS001 was well-tolerated by the recipients. Moreover, when the subjects in the study were dosed twice daily with LT-NS001 for seven days, plasma concentrations of naproxen were within the therapeutic range.
LT-NS001 is a prodrug, which is converted in the bloodstream into naproxen, a non-steroidal anti-inflammatory drug. The company expects to begin enrolling subjects in its next clinical study of LT-NS001 later 2008.
Mitchell Fink, president and CEO of Logical Therapeutics, said: “The results from our recently completed Phase Ib study of LT-NS001 are very encouraging, because they show that administration of the pro-drug leads to clinically useful circulating levels of naproxen.”